External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors.
5-alpha reductase inhibitor
Predictive model
Risk calculator
Significant prostate cancer
Validation
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
received:
01
12
2023
accepted:
25
05
2024
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
epublish
Résumé
To validate the Barcelona-magnetic resonance imaging predictive model (BCN-MRI PM) for clinically significant prostate cancer (csPCa) in Catalonia, a Spanish region with 7.9 million inhabitants. Additionally, the BCN-MRI PM is validated in men receiving 5-alpha reductase inhibitors (5-ARI). A population of 2,212 men with prostate-specific antigen serum level > 3.0 ng/ml and/or a suspicious digital rectal examination who underwent multiparametric MRI and targeted and/or systematic biopsies in the year 2022, at ten participant centers of the Catalonian csPCa early detection program, were selected. 120 individuals (5.7%) were identified as receiving 5-ARI treatment for longer than a year. The risk of csPCa was retrospectively assessed with the Barcelona-risk calculator 2 (BCN-RC 2). Men undergoing 5-ARI treatment for less than a year were excluded. CsPCa was defined when the grade group was ≥ 2. The area under the curve of the BCN-MRI PM in 5-ARI naïve men was 0.824 (95% CI 0.783-0.842) and 0.849 (0.806-0.916) in those receiving 5-ARI treatment, p 0.475. Specificities at 100, 97.5, and 95% sensitivity thresholds were to 2.7, 29.3, and 39% in 5-ARI naïve men, while 43.5, 46.4, and 47.8%, respectively in 5-ARI users. The application of BCN-MRI PM would result in a reduction of 23.8% of prostate biopsies missing 5% of csPCa in 5-ARI naïve men, while reducing 25% of prostate biopsies without missing csPCa in 5-ARI users. The BCN-MRI PM has achieved successful validation in Catalonia and, notably, for the first time, in men undergoing 5-ARI treatment.
Identifiants
pubmed: 38985325
doi: 10.1007/s00345-024-05092-0
pii: 10.1007/s00345-024-05092-0
doi:
Substances chimiques
5-alpha Reductase Inhibitors
0
Types de publication
Journal Article
Validation Study
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
393Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328
doi: 10.1056/NEJMoa0810084
pubmed: 19297566
Frånlund M, Månsson M, Godtman RA, Aus G, Holmberg E, Kollberg KS, Lodding P, Pihl CG, Stranne J, Lilja H, Hugosson J (2022) Results from 22 years of Followup in the Göteborg Randomized Population-based prostate Cancer screening trial. J Urol 208:292–300
doi: 10.1097/JU.0000000000002696
pubmed: 35422134
pmcid: 9275849
Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M (2022) Serum PSA-based early detection of prostate cancer in Europe and globally: past, present, and future. Nat Rev Urol 19:562–572
doi: 10.1038/s41585-022-00638-6
pubmed: 35974245
Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N’Dow J, Sønksen J, Stenzl A, Wirth M (2021) Prostate-specific Antigen Testing as Part of a risk-adapted early detection strategy for prostate Cancer: European Association of Urology Position and recommendations for 2021. Eur Urol 80:703–711
doi: 10.1016/j.eururo.2021.07.024
pubmed: 34407909
Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ (2021) A European model for an organised risk-stratified early detection Programme for prostate Cancer. Eur Urol Oncol 4:731–739
doi: 10.1016/j.euo.2021.06.006
pubmed: 34364829
Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Escobar M, Mast R, de Torres IM, Semidey ME, Abascal JM, Sola C, Servian P, Salvador D, Santamaría A, Planas J, Esteban LM, Trilla E (2022) The Barcelona Predictive Model of clinically significant prostate Cancer. Cancers (Basel) 14:1589
doi: 10.3390/cancers14061589
pubmed: 35326740
Morote J, Borque-Fernando Á, Triquell M, Campistol M, Servian P, Abascal JM, Planas J, Méndez O, Esteban LM, Trilla E (2023) Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting clinically significant prostate Cancer. Eur Urol Open Sci 53:46–54
doi: 10.1016/j.euros.2023.03.013
pubmed: 37441350
pmcid: 10334241
Jacobsen SJ, Girman CJ, Lieber MM (2001) Natural history of benign prostatic hyperplasia. Urology 58:5–16
doi: 10.1016/S0090-4295(01)01298-5
pubmed: 11750242
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224
doi: 10.1056/NEJMoa030660
pubmed: 12824459
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, and REDUCE SG (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202
doi: 10.1056/NEJMoa0908127
pubmed: 20357281
Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG (2013) Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 369:603–610
doi: 10.1056/NEJMoa1215932
pubmed: 23944298
pmcid: 4141537
Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N (2018) Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer. Curr Opin Urol 28:46–54
doi: 10.1097/MOU.0000000000000455
pubmed: 29028765
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading C (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol 40:244–252
Triquell M, Campistol M, Celma A, Regis L, Cuadras M, Planas J, Trilla E, Morote J (2022) Magnetic resonance imaging-based predictive models for clinically significant prostate Cancer: a systematic review. Cancers (Basel) 14:4747
doi: 10.3390/cancers14194747
pubmed: 36230670
Kim JK, Lee HJ, Hwang SI, Choe G, Kim HJ, Hong SK (2019) The effect of 5 alpha-reductase inhibitor therapy on prostate cancer detection in the era of multi-parametric magnetic resonance imaging. Sci Rep 9:17862
doi: 10.1038/s41598-019-54464-9
pubmed: 31780771
pmcid: 6882845
Wang Z, Wang K, Ong HY, Tsang WC, Wu QH, Chiong E (2023) 5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity. BMC Urol 23:61
doi: 10.1186/s12894-023-01235-4
pubmed: 37061671
pmcid: 10105450
Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, Ricapito A, Luzzago S, Ferro M, Musi G, Totaro A, Racioppi M, Carbonara U, Checcucci E, Manfredi M, D’Aietti D, Porcaro AB, Nordström T, Björnebo L, Oderda M, Soria F, Taimen P, Aronen HJ, Perez IM, Ettala O, Marchioni M, Simone G, Ferriero M, Brassetti A, Napolitano L, Carmignani L, Signorini C, Conti A, Ludovico G, Scarcia M, Trombetta C, Claps F, Traunero F, Montanari E, Boeri L, Maggi M, Del Giudice F, Bove P, Forte V, Ficarra V, Rossanese M, Mucciardi G, Pagliarulo V, Tafuri A, Mirone V, Schips L, Antonelli A, Gontero P, Cormio L, Sciarra A, Porpiglia F, Bassi P, Ditonno P, Boström PJ, Messina E, Panebianco V, De Cobelli O, Carrieri G, and PROMOD SG (2023) Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. World J Urol 41:2967–2974
doi: 10.1007/s00345-023-04634-2
pubmed: 37787941
pmcid: 10632288
Marberger M, Freedland SJ, Andriole GL, Emberton M, Pettaway C, Montorsi F, Teloken C, Rittmaster RS, Somerville MC, Castro R (2012) Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 109:1162–1169
doi: 10.1111/j.1464-410X.2011.10373.x
pubmed: 21699645
Chang LW, Wang SS, Yang CK, Lu K, Chen CS, Cheng CL, Hung SC, Chiu KY, Hsu CY, Li JR (2023) Risk analysis of prostate Cancer Development following five-alpha reductase inhibitor treatment for benign prostate Hyperplasia. Anticancer Res 43:485–491
doi: 10.21873/anticanres.16185
pubmed: 36585197
Moore CM, Robertson NL, Jichi F, Damola A, Ambler G, Giganti F, Ridout AJ, Bott SR, Winkler M, Ahmed HU, Arya M, Mitra AV, McCartan N, Freeman A, Jameson C, Castro R, Gambarota G, Whitcher BJ, Allen C, Kirkham A, Emberton M (2017) The Effect of Dutasteride on magnetic resonance imaging defined prostate Cancer: MAPPED-A Randomized, Placebo Controlled, double-blind clinical trial. J Urol 197:1006–1013
doi: 10.1016/j.juro.2016.11.090
pubmed: 27871928
Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Gambarota G, Whitcher B, Castro R, Emberton M, Allen C, Kirkham A (2017) MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. Eur Radiol 27:4767–4774
doi: 10.1007/s00330-017-4858-0
pubmed: 28523355
pmcid: 5635085
Giganti F, Gambarota G, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Whitcher B, Castro-Santamaria R, Emberton M, Allen C, Kirkham A (2018) Prostate cancer detection using quantitative T2 and T2 -weighted imaging: the effects of 5-alpha-reductase inhibitors in men on active surveillance. J Magn Reson Imaging 47:1646–1653
doi: 10.1002/jmri.25891
pubmed: 29135073
Starobinets O, Kurhanewicz J, Noworolski SM (2017) Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort. NMR Biomed 30:e3696
doi: 10.1002/nbm.3696
Forte V, Cavallo AU, Bertolo R, de Soccio V, Sperandio M, Bove P, Ciccariello M (2021) PI-RADS score v.2 in predicting malignancy in patients undergoing 5α-reductase inhibitor therapy. Prostate Cancer Prostatic Dis 24:150–155
doi: 10.1038/s41391-020-0256-9
pubmed: 32681155
Morote J, Borque-Fernando Á, Triquell M, Esteban LM, Trilla E (2022) The true utility of Predictive models based on magnetic resonance imaging in selecting candidates for prostate biopsy. Eur Urol Open Sci 42:40–41
doi: 10.1016/j.euros.2022.06.002
pubmed: 35795075
pmcid: 9251714
Diniz MA (2022) Statistical methods for validation of predictive models. J Nucl Cardiol 29:3248–3255
doi: 10.1007/s12350-022-02994-7
pubmed: 35610537
Nandi A, Xhafa F (2022) A federated learning method for real-time emotion state classification from multi-modal streaming. Methods 204:340–347
doi: 10.1016/j.ymeth.2022.03.005
pubmed: 35314343
Strobl AN, Vickers AJ, Van Calster B, Steyerberg E, Leach RJ, Thompson IM, Ankerst DP (2015) Improving patient prostate cancer risk assessment: moving from static, globally-applied to dynamic, practice-specific risk calculators. J Biomed Inf 56:87–93
doi: 10.1016/j.jbi.2015.05.001